Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants

Phase 3 Completed 193 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in infants of Japanese descent.

Timeline

Start: 2007-09
Primary completion: 2008-08
Completion: 2008-08

Publications

Togashi T, Yamaji M, Thompson A, Giardina PC, Aizawa M, Patterson S, Gruber WC, Scott DA; 3003 Study Group. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan. Pediatr Infect Dis J. 2013 Sep;32(9):984-9. doi: 10.1097/INF.0b013e318293007e.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prevnar 13	Vaccine	—	Subcutaneous

Indications

No indication recorded.